Literature DB >> 21789616

Osteomalacia caused by tumors in facies cranii mimicking rheumatoid arthritis.

Wang Xian-Ling1, Ba Jian-Ming, Zhong Wen-Wen, Lü Zhao-Hui, Dou Jing-Tao, Lu Ju-Ming, Mu Yi-Ming.   

Abstract

Tumor-induced osteomalacia (TIO) is an extremely rare metabolic bone disease and the occult offending tumor arising in facies cranii is even more uncommon. In this report, we described 2 middle-aged females with TIO caused by the tumor in facies cranii, which had ever been misdiagnosed as rheumatoid arthritis. Case 1 was present with diffuse bone pain and muscle weakness for 4 years, as well as esotropia in the right eye for 1 month. Case 2 was present with progressive bone pain in low back and hip for 2 years. Biochemical studies both showed persistent hypophosphatemia and urinary over wasting phosphate. Radiological examinations revealed the infiltrative mass in right apex partis petrosae ossis temporalis in case 1, and the soft mass in left nasal cavity and ethmoid sinuses in case 2, respectively. The offending tumors were resected completely in case 2, however, incompletely in case 1. Pathology examination revealed mixed connective tissue variant phosphaturic mesenchymal tumors. In conclusion, TIO should be presumed in patients presenting with unexplained persistent hypophosphatemia osteomalacia, also a thorough detection for tumor in facies cranii should be performed.

Entities:  

Mesh:

Year:  2011        PMID: 21789616     DOI: 10.1007/s00296-011-2018-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  12 in total

1.  Octreotide for tumor-induced osteomalacia.

Authors:  Federica Paglia; Simona Dionisi; Salvatore Minisola
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

2.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

3.  Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia.

Authors:  Karsten Müssig; Mehmet Ozer Oksüz; Christina Pfannenberg; Patrick Adam; Jozef Zustin; Stefan Beckert; Stephan Petersenn
Journal:  J Clin Endocrinol Metab       Date:  2009-09-29       Impact factor: 5.958

4.  Mesenchymal phosphaturic neoplasm in the maxillary sinus: a case report.

Authors:  M Pedrazzoli; G Colletti; M Ferrari; G Rossetti; L Moneghini; L Autelitano
Journal:  Int J Oral Maxillofac Surg       Date:  2010-05-21       Impact factor: 2.789

5.  Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature.

Authors:  Yoshiyuki Mori; Toru Ogasawara; Toru Motoi; Yuichiro Shimizu; Daichi Chikazu; Kazumi Tamura; Seiji Fukumoto; Tsuyoshi Takato
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-03

6.  Oncogenic osteomalacia in a patient with an ethmoid sinus tumour.

Authors:  R Kurien; M T Manipadam; V Rupa
Journal:  J Laryngol Otol       Date:  2009-12-11       Impact factor: 1.469

7.  Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis.

Authors:  M Odette Gore; Brian J Welch; Weidong Geng; Wareef Kabbani; Naim M Maalouf; Joseph E Zerwekh; Orson W Moe; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2008-07-30       Impact factor: 10.612

8.  Tumor-induced osteomalacia: successful treatment by radio-guided tumor surgery.

Authors:  Birgit Harbeck; Harald Schöcklmann; Andreas Seekamp; Norbert Czech; Heiner Mönig
Journal:  J Clin Rheumatol       Date:  2009-02       Impact factor: 3.517

9.  Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.

Authors:  Erik A Imel; Munro Peacock; Pisit Pitukcheewanont; Howard J Heller; Leanne M Ward; Dorothy Shulman; Moustapha Kassem; Paula Rackoff; Mark Zimering; Alan Dalkin; Elaine Drobny; Giacomo Colussi; Joseph L Shaker; Elizabeth H Hoogendoorn; Siu L Hui; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2006-03-21       Impact factor: 5.958

10.  Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.

Authors:  Itsuro Endo; Seiji Fukumoto; Keiichi Ozono; Noriyuki Namba; Hiroyuki Tanaka; Daisuke Inoue; Masanori Minagawa; Toshitsugu Sugimoto; Mika Yamauchi; Toshimi Michigami; Toshio Matsumoto
Journal:  Bone       Date:  2008-03-05       Impact factor: 4.398

View more
  5 in total

Review 1.  Phosphaturic Mesenchymal Tumor: 2 New Oral Cases and Review of 53 Cases in the Head and Neck.

Authors:  Hiba Qari; Aya Hamao-Sakamoto; Clay Fuselier; Yi-Shing Lisa Cheng; Harvey Kessler; John Wright
Journal:  Head Neck Pathol       Date:  2015-11-14

2.  Persistence and recurrence in tumor-induced osteomalacia: A systematic review of the literature and results from a national survey/case series.

Authors:  Luisella Cianferotti; Chiara Delli Poggi; Francesco Bertoldo; Carla Caffarelli; Chiara Crotti; Davide Gatti; Sandro Giannini; Stefano Gonnelli; Maurizio Mazzantini; Viapiana Ombretta; Stefania Sella; Angela Setti; Massimo Varenna; Francesca Zucchi; Maria Luisa Brandi
Journal:  Endocrine       Date:  2022-04-05       Impact factor: 3.925

Review 3.  Phosphaturic mesenchymal tumor with an admixture of epithelial and mesenchymal elements in the jaws: clinicopathological and immunohistochemical analysis of 22 cases with literature review.

Authors:  Huanwen Wu; Marilyn M Bui; Lian Zhou; Dongmei Li; Hui Zhang; Dingrong Zhong
Journal:  Mod Pathol       Date:  2018-09-11       Impact factor: 7.842

4.  Is there any link between tumor-induced osteomalacia and psoriasis? A case report.

Authors:  Mojtaba Akbari; Bagher Larijani; Sasan Sharghi; Ali Jalili; Sayed Mahmoud Sajjadi-Jazi
Journal:  J Diabetes Metab Disord       Date:  2017-08-23

5.  Tumor induced osteomalacia in head and neck region: single center experience and systematic review.

Authors:  Ravikumar Shah; Anurag R Lila; Ramteke-Swati Jadhav; Virendra Patil; Abhishek Mahajan; Sushil Sonawane; Puja Thadani; Anil Dcruz; Prathamesh Pai; Munita Bal; Subhada Kane; Nalini Shah; Tushar Bandgar
Journal:  Endocr Connect       Date:  2019-10       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.